Abstract 945: Advancing Cancer Immunotherapeutics: A Focus on Characterization of Anti-Ctla-4 Mabs for Better Anti-Tumor Immunity and Less Toxicity
Xuexiang Du,Mingyue Liu,Yan Zhang,Fei Tang,Chunxia Ai,Peng Zhang,Pan Zheng,Yang Liu
DOI: https://doi.org/10.1158/1538-7445.am2020-945
IF: 11.2
2020-01-01
Cancer Research
Abstract:Abstract Anti-CTLA-4 monoclonal antibodies confer a cancer immunotherapeutic effect (CITE) but cause severe immunotherapy-related adverse events (irAEs). How to uncouple the undesired irAEs from the beneficial CITE seen in cancer patients treated with anti-CTLA-4 and/or other checkpoints inhibitors has proven to be a daunting challenge, partially due to the lack of the understanding of the real MOA(mechanism of Action) of CITE and irAEs. Meanwhile, an animal model, which recapitulates clinical irAE and CITE, would be valuable for developing safer CTLA-4-targeting reagents. We not only discovered that the immunotherapy of current anti-CTLA-4 mAbs were dependent on Fc/Fc receptor mediated intra-tumor Treg depletion rather than the widely held mechanism of checkpoint blockade, which raised the reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy, we also establish one realistic irAEs model and find one mechanism of irAEs. In this model, the clinically used drug Ipilimumab (or TremeIgG1) induced severe irAEs especially when combined with an anti-PD-1 antibody; whereas another mAb L3D10 induced comparable CITE with very mild irAE under the same conditions. Humanization (HL12/HL32) of L3D10, which led to the loss of blocking activity, further increased safety without affecting the therapeutic effect. Furthermore, we report that while irAE-prone Ipilimumab and TremeIgG1 rapidly direct cell surface CTLA-4 for lysosomal degradation, the non-irAE-prone antibodies we generated, HL12 or HL32, dissociate from CTLA-4 after endocytosis and allow CTLA-4 recycling to cell surface, increasing the pH sensitivity of TremeIgG1 by introducing designed tyrosine-to-histidine mutations prevents antibody-triggered lysosomal CTLA-4 downregulation and dramatically attenuates irAE. Our data establish a new paradigm for cancer research that allows for abrogating irAE while increasing CITE of anti-CTLA-4 antibodies. Citation Format: Xuexiang Du, Mingyue Liu, Yan Zhang, Fei Tang, Chunxia Ai, Peng Zhang, Pan Zheng, Yang Liu. Advancing cancer immunotherapeutics: A focus on characterization of anti-CTLA-4 mAbs for better anti-tumor immunity and less toxicity [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 945.